Drug intelligence / Profile preview

9-methyl-beta-carboline

Development stage
Preclinical
Modality
Small Molecules
Administration
Oral, Intrathecal
01

Overview

9-methyl-beta-carboline (9-me-bc) is a heterocyclic amine and a derivative of the beta-carboline family, primarily investigated for its neuroprotective and neurorestorative properties. It is distinguished by its ability to stimulate the growth of dopaminergic neurons and increase the expression of key neurotrophic factors, including brain-derived neurotrophic factor (BDNF) and ciliary neurotrophic factor (CNTF). Mechanistically, it enhances the activity of mitochondrial complex I (NADH dehydrogenase) and acts as a reversible inhibitor of monoamine oxidase (MAO). In animal models of Parkinson's disease, 9-me-bc has demonstrated the capacity to reverse dopamine depletion and restore tyrosine hydroxylase-positive neurons in the substantia nigra. While it is popular in the nootropics community as a cognitive enhancer, it remains in the preclinical stage of research and has not been approved for clinical use by regulatory agencies.

Other names
9-methyl-9H-pyrido[3,4-b]indole9-Methylnorharman
02

Targets

DAT (Dopamine plasma membrane transport protein)MAOA (Monoamine oxidase A)MAOB (Monoamine oxidase B)OCT (Organic cation transporter family)BDNF (Brain-derived neurotrophic factor)CNTF (Ciliary neurotrophic factor)CDNF (Cerebral dopamine neurotrophic factor)ND1 (Mitochondrial electron transport chain complex I)

Beyond the preview

Go deeper on 9-methyl-beta-carboline.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on 9-methyl-beta-carboline.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call